CureSCi Metadata Catalog—Finding and harmonizing studies for secondary analysis of hydroxyurea discontinuation in sickle cell disease
Open Access
- 23 April 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0309572
Abstract
Objectives: Sickle cell disease (SCD) is a rare group of inherited red blood cell disorders that affect hemoglobin, resulting in serious multi-system complications. The limited number of patients available to participate in research studies can inhibit investigating sophisticated relationships. Secondary analysis is a research method that involves using existing data to answer new research questions. Data harmonization enables secondary analysis by combining data across studies, especially helpful for rare disease research where individual studies may be small. The National Heart, Lung, and Blood Institute Cure Sickle Cell Initiative (CureSCi) Metadata Catalog is a web-based tool to identify SCD study datasets for conducting data harmonization and secondary analysis. We present a proof-of-concept secondary analysis to explore factors associated with discontinuation of hydroxyurea, a safe and effective first line SCD therapy, to illustrate the utility of the CureSCi Metadata Catalog to expedite and enable more robust SCD research. Methods: We performed secondary analysis of SCD studies using a multi-step workflow: develop research questions, identify study datasets, identify variables of interest, harmonize variables, and establish an analysis method. A harmonized dataset consisting of eight predictor variables across five studies was created. Secondary analysis employed a generalized linear model to identify factors that significantly impact hydroxyurea discontinuation. Results: The CureSCi Metadata Catalog provided a platform to efficiently find relevant studies and design a harmonization strategy to prepare data for secondary analysis. Multivariate analysis of the harmonized data identified that patients who were female, had a history of blood transfusion therapy, experiencing pain, and had the SC sickle cell genotype are more likely to stop hydroxyurea treatment. Conclusion: This secondary analysis provides a template for how the CureSCi Metadata Catalog expedites dataset discovery of sickle cell studies for identifying relationships between variables or validating existing findings.Keywords
Funding Information
- National Institutes of Health (OT3 HL147798)
This publication has 30 references indexed in Scilit:
- Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021The Lancet Haematology, 2023
- Sickle Cell DiseaseJAMA, 2022
- Pregnancy outcomes with hydroxyurea use in women with sickle cell diseaseAmerican Journal of Hematology, 2022
- Effective Recruitment Strategies for a Sickle Cell Patient Registry Across Sites from the Sickle Cell Disease Implementation Consortium (SCDIC)Journal of Immigrant and Minority Health, 2020
- Oxidative stress assessment in sickle cell anemia patients treated with hydroxyureaAnnals of Hematology, 2020
- Hydroxyurea use in young infants with sickle cell diseasePediatric Blood & Cancer, 2019
- Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)Transplantation and Cellular Therapy, 2012
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Health‐related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial ConsortiumPediatric Blood & Cancer, 2010
- Hydroxyurea in sickle cell disease—A study of clinico-pharmacological efficacy in the Indian haplotypeBlood Cells, Molecules, and Diseases, 2009